Does Erectile Dysfonction Allow to Evaluate Subendocardial Viability Among Treated Patients With Hypertension ?

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Erectile dysfunction (ED) is associated with subclinical atherosclerosis and may precede clinically apparent coronary artery disease by two to five years. It may therefore serve as an early warning sign of cardiovascular disease and help identify patients who could benefit from intensified cardiovascular risk-factor management. The subendocardial viability ratio (SEVR), also known as the Buckberg index, is obtained noninvasively from radial artery applanation tonometry. SEVR reflects the balance between myocardial oxygen supply and demand and has been associated with coronary flow reserve in patients with hypertension. The DEVISE study will compare SEVR between treated men with hypertension who have ED with those who do not. The study will also examine the associations between ED severity and arterial stiffness, central hemodynamics, exercise capacity, left ventricular mass, coronary artery calcium, high-sensitivity C-reactive protein, cardiovascular risk, and quality of life.

The question addressed in our study is whether an alteration in subendocardial viability represents subclinical coronary disease associated with ED.

Eligibility criteria

Qualifiers

Male participant aged 18 years or older.

Confirmed diagnosis of hypertension.

Receiving pharmacological antihypertensive treatment.

Consecutively admitted to the hypertension day-hospital unit for assessment of hypertension-mediated organ damage.

Disqualifiers

Permanent atrial fibrillation

Recurrent cardiac arrhythmias

Not affiliated with a French social security scheme

Opposition to participation

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

120 Participants
are grouped into 2 trial groups